Prevention of viral hepatitis (B and C) reassessed

Best Practice and Research: Clinical Gastroenterology

Volumn 22, Issue 6, 2008, Pages 1009-1029

  Van Herck, Koen ^a   Vorsters, A ^a   Van Damme, P ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

hepatitis B; hepatitis C; prevention; risk groups; vaccination

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; HEPATITIS C VACCINE; NUCLEOSIDE ANALOG; PEGINTERFERON; RIBAVIRIN;

ABDOMINAL PAIN; ANAPHYLAXIS; ARTICLE; ASEPSIS; BLOOD ANALYSIS; BLOOD TRANSFUSION; COMORBIDITY; CONTINUING EDUCATION; DISINFECTION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; EPIDEMIOLOGICAL DATA; FATIGUE; FEVER; HEADACHE; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HEALTH EDUCATION; HEALTH PROGRAM; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; INFECTION CONTROL; INFECTION PREVENTION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE SWELLING; INTRAVENOUS DRUG ABUSE; NAUSEA; NEEDLESTICK INJURY; OCCUPATIONAL HAZARD; PATIENT COUNSELING; PERSONAL HYGIENE; PREVALENCE; PUBLIC HEALTH PROBLEM; PUBLIC HEALTH SERVICE; RISK REDUCTION; SAFE SEX; SCREENING TEST; SEXUAL TRANSMISSION; TREATMENT OUTCOME; VERTICAL TRANSMISSION; VIRUS TRANSMISSION;

DISEASE OUTBREAKS; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS C; HUMANS; PREVENTIVE HEALTH SERVICES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; WORLD HEALTH;

EID: 58949095817     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2008.11.008     Document Type: Article

References (95)

1. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II: immunization of adults. MMWR Morb Mortal Wkly Rep 55 No. RR-16 (2006) 1-25
2. FitzSimons D., François G., De Carli G., et al. Hepatitis B virus, hepatitis C virus and other blood-borne infections in health-care workers: guidelines for prevention and management in industrialised countries. Occup Environ Med 65 (2008) 446-451
3. Sherlock S. Clinical features of hepatitis. In: Zuckerman A.J., and Thomas H.S. (Eds). Viral Hepatitis (1993), Churchill Livingstone, London 1-11
4. Chen C.J., Yang H.I., Su J., et al. Risk of HCC across a biological gradient of serum HBV-DNA levels. JAMA 295 (2006) 65-73
5. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11 (2004) 97-107
6. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 34 Suppl. 1 (2005) S1-S3
7. Mahoney F.J. Update on diagnosis, management and prevention of hepatitis B virus infection. Clin Microbiol Rev 12 (1999) 351-366
8. Goldstein S.T., Zhou F., Hadler S.C., et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34 (2005) 1329-1339. http://aim.path.org/en/vaccines/hepb/assessBurden/model/index.html [accessed 17.09.08]
9. World Health Organization. Informal Consultation on Quadrivalent Diphtheria-Tetanus-Pertussis-Hepatitis B vaccine. Final Report (1992) (1992), World Health Organization, Geneva
10. World Health Organization. Hepatitis B vaccines (WHO position paper). Wkly Epidemiol Rec 79 (2004) 255-263
11. Tandon B.N., and Tandon A. Epidemiological trends of viral hepatitis in Asia. In: Rizzetto M., Purcell R.H., Gerin J.L., and Verme G. (Eds). Viral Hepatitis and Liver Disease (1997), Edizioni Minerva Medica, Turin 559-561
12. Szmuness W., Stevens C.E., Zang E.A., et al. A controlled clinical trial of the efficacy of the hepatitis B vaccine (Hepatavax B): a final report. Hepatology 5 (1981) 377-385
13. Centers for Disease Control and Prevention, and Recommendations of the Immunization Practices Advisory Committee. Update on hepatitis B prevention. Morb Mortal Wkly Rep 36 (1987) 353-360
14. Rendi-Wagner P., Shouval D., Genton B., et al. Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine 24 (2006) 2781-2789
15. Van Damme P., and Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 5 (2007) 79-84
16. Van Herck K., Leuridan E., and Van Damme P. Schedules for hepatitis B vaccination of risk groups: balancing immunogenicity and compliance. Sex Transm Infect 83 (2007) 426-432
17. Niu M.T. Review of 12 million doses shows hepatitis B vaccine safe. Vaccine Wkly 4 (1996) 13-15
18. Duclos P. Safety of immunization and adverse events following vaccination against hepatitis B. J Hepatol 39 (2003) S83-S88
19. Safary A., and André F. Over a decade of experience with the yeast recombinant hepatitis B vaccine. Vaccine 18 (1999) 57-67
20. Venters C., Graham W., and Cassidy W. Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines 3 (2004) 119-129
21. Hilleman M.R., Buynak E.B., Roehm R.R., et al. Purified and inactivated human hepatitis B vaccine: a progress report. Am J Med Sci 270 (1975) 401-404
22. Keating G.M., and Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 63 (2003) 1021-1051
23. Dienstag J.L., Werner B.G., Polk B.F., et al. Hepatitis B vaccine in health-care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 82 (1984) 8168-8172
24. Alper C.A. The human immune response to hepatitis B surface antigen. Exp Clin Immunogenet 12 (1995) 171-181
25. Hollinger F.B. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines and vaccine protocol recommendations. Am J Med 87 Suppl. 3A (1989) 36-40
26. Hadler S.C., and Margolis H.S. Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. In: Remington J.S., and Swartz M.N. (Eds). Current Topics In Infectious Diseases vol. 12 (1992), Blackwell Scientific Publications, Boston 282-308
27. Kao J.-H., and Chen D.S. Hepatitis B vaccination: to boost or not to boost?. Lancet 366 (2005) 1337-1338
28. Zanetti A.R., Mariano A., Romanò L., et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 366 (2005) 1379-1384
29. West D.J., and Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 14 (1996) 1019-1027
30. Banatvala J.E., and Van Damme P. Hepatitis B vaccine-do we need boosters?. J Hepatol 10 (2003) 1-6
31. European Consensus Group on Hepatitis B immunity. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 355 (2000) 561-565
32. Polizzotto M.N., Wood E.M., Ingham H., et al. Reducing the risk of transfusion-transmissible viral infection through blood donor selection: the Australian experience 2000 through 2006. Transfusion 48 (2008) 55-63
33. World Health Organization. Vaccines and biologicals. WHO vaccine preventable disease monitoring system. Global summary. (data up to 2005). Available from: (2006). http://www.who.int/vaccines-documents/GlobalSummary/GlobalSummary.pdf [accessed 17.09.08]
34. André F.E., and Zuckerman A.J. Review: protective efficacy of hepatitis B vaccines in neonates. J Med Virol 44 (1994) 144-151
35. World Health Organization. Expanded Programme on Immunization. Introduction of Hepatitis B Vaccination into Childhood Immunization Services: Management Guidelines, Including Information for Health Workers and Parents (WHO/V&B/01.31) (2001), World Health Organization, Geneva. http://www.who.int/vaccines-documents/DocsPDF01/www613.pdf [accessed 17.09.08]
36. Van Herck K., and Van Damme P. Benefits of early hepatitis B immunization programs for newborns and infants. Pediatr Infect Dis J 27 (2008) 861-869
37. Coursaget P., Leboulleux D., Soumare M., et al. Twelve-year follow-up study of hepatitis B immunisation of Senegalese infants. J Hepatol 21 (1994) 250-254
38. Werner B.G., and Grady G.F. Accidental hepatitis-B-surface-antigen-positive inoculations: use of e antigen to estimate infectivity. Ann Intern Med 97 (1982) 367-369
39. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep 50 RR-11 (2001) 1-42
40. Van Wijk P.T., Pelk-Jongen M., Wijkmans C., et al. Variation in interpretation and counselling of blood exposure incidents by different medical practitioners. Am J Infect Control 36 (2008) 123-128
41. Simard E.P., Miller J.T., George P.A., et al. Hepatitis B vaccination coverage levels among health-care workers in the United States, 2002-2003. Infect Control Hosp Epidemiol 28 (2007) 783-790
42. Gunson R.N., Shouval D., Roggendorf M., et al., European Consensus Group. Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in health care workers (HCWs): guidelines for prevention of transmission of HBV and HCV from HCW to patients. J Clin Virol 27 (2003) 213-230
43. Viral Hepatitis Prevention Board. Hepatitis B vaccination: how to reach risk groups. Viral Hepatitis Prevention Board meeting, Ghent, Belgium, March 15-16, 2001. J Viral Hepat 10 (2001) 1-20
44. Baral S., Sherman S.G., Millson P., et al. Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect Dis 7 (2007) 667-674
45. De P., Cox J., Boivin J.-F., et al. The importance of social networks in their association to drug equipment sharing among injection drug users: a review. Addiction 102 (2007) 1730-1739
46. Mast E.E., and Ward J.W. Hepatitis B vaccines. In: Plotkin S., Orenstein W., and Offit P. (Eds). Vaccines. 5th ed. (2008), Saunders Elsevier 205-241
47. Finelli L., and Bell B.P. Chapter 4: hepatitis B. In: Roush S.W., McIntyre L., and Baldy L. (Eds). Manual for the Surveillance of Vaccine-preventable Diseases. 4th ed. (2008), Centers for Disease Control and Prevention, Atlanta, GA. United States. Available from: http://www.cdc.gov/vaccines/pubs/surv-manual/ [accessed 16.09.08]
48. Choo Q.L., Kuo G., Weiner A.J., et al. Isolation of a cDNA clone derived from a blood-born non-A, non-B viral hepatitis genome. Science 244 (1989) 359-362
49. Schreiber G.B., Busch M.P., Kleinman S.H., et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 334 (1996) 1685-1690
50. Shepard C.W., Finelli L., and Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5 (2005) 558-567
51. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 45 (2006) 607-616
52. Esteban J.I., Sauleda S., and Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 48 (2008) 148-162
53. Wasley A., and Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20 (2000) 1-16
54. Puro V., Petrosillo N., and Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on occupational risk of HIV and other bloodborne infections. Am J Infect Control 23 (1995) 273-277
55. Tumminelli F., Marcellin P., Rizzo S., et al. Shaving as potential source of hepatitis C virus infection. Lancet 345 (1995) 658
56. Sun D.X., Zhang F.G., Geng Y.Q., et al. Hepatitis C transmission by cosmetic tattooing in women. Lancet 347 (1996) 541
57. Terrault N.A. Sexual activity as a risk factor for hepatitis C. Hepatology 36 5 Suppl 1 (2002) S99-S105
58. Hahn J.A. Sex, Drugs, and Hepatitis C Virus. J Invest Dermatol 195 (2007) 1556-1559
59. Memon M.I., and Memon M.A. Hepatitis C: an epidemiological review. J Viral Hepat 9 (2002) 84-100
60. Wang C.C., Krantz E., Klarquist J., et al. Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 196 (2007) 1474-1482
61. Herschow R.C., O'Driscoll P.T., Handelsman E., et al. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, clinical progression to AIDS or death among HIV-infected women: women and infants transmission study. Clin Infect Dis 40 (2005) 859-867
62. Zanetti A.R., Tanzi E., Romano L., et al. Multicenter trial on mother-to-infant transmission of GBV-C virus. The Lombardy Study Group on Vertical/Perinatal Hepatitis Viruses Transmission. J Med Virol 54 (1998) 107-112
63. Jonas M.M. Children with hepatitis C. Hepatology 36 5 Suppl. 1 (2002) S173-S178
64. Boxall E., Baumann K., Price N., et al. Discordant outcome of perinatal transmission of hepatitis C in twin pregnancies. J Clin Virol 38 (2007) 91-95
65. Coppola N., Pisapia R., Marrocco C., et al. Anti-HCV IgG avidity index in acute hepatitis C. J Clin Virol 40 (2007) 110-115
66. Kato N., Ootsuyama Y., Nakazawa T., et al. Genetic drift in hypervariable region I of the viral genome in persistent hepatitis C virus infection. J Virol 68 (1994) 4776-4784
67. Irving W.L., Salmon D., Boucher C., et al. Acute hepatitis C virus infection. Euro Surveill 13 (2008) 1-4. Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=18879
68. Alter M.J. Epidemiology of hepatitis C virus infection. World J Gastroenterol 13 (2007) 2436-2441
69. Kew M., Francois G., Lavanchy D., et al. Prevention of hepatitis C virus infection. J Viral Hepat 11 (2004) 198-205
70. Anonymous. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board. J Viral Hepat 6 (1999) 35-47
71. Purcell R.H. Hepatitis viruses: changing patterns of human disease. Proc Natl Acad Sci USA 91 (1994) 2401-2490
72. Frank C., Mohamed M.K., Strickland G.T., et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 355 (2000) 887-891
73. Mathei C., Buntinx F., and Van Damme P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepat 9 (2002) 157-173
74. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep 50 (2001) 1-43
75. World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6 (1999) 35-47
76. Jadoul M.Y. Patient-to-patient transmission of hepatitis C. Ann Intern Med 143 (2005) 761
77. National Institutes of Health. NIH Consensus Development Conference Statement: management of hepatitis C 2002. Gastroenterology 123 (2002) 2082-2099
78. Lindenbach B.D., Thiel H.J., and Rice C.M. Flaviviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. 5th ed. (2007), Lippincott-Raven Publishers, Philadelphia
79. Weiner A.J., Brauer M.J., Rosenblatt J., et al. Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology 180 (1991) 842-848
80. Kato N., Sekiya H., Ootsuyama Y., et al. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus. J Virol 67 (1993) 3923-3930
81. Farci P., Shimoda A., Coiana A., et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 (2000) 339-344
82. Bowen D.G., and Walker C.M. Mutational escape from CD8 + T-cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 201 (2005) 1709-1714
83. Lindenbach B.D., and Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 436 (2005) 933-938
84. Wakita T., Pietschmann T., Kato T., et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11 (2005) 791-796
85. Zhong J., Gastaminza P., Chung J., et al. Persistent hepatitis C virus infection in vitro: co-evolution of virus and host. J Virol 80 (2006) 11082-11093
86. Lohmann V., Korner F., Koch J., et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285 (1999) 110-113
87. Bartenschlager R. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. Curr Opin Microbiol 9 (2006) 416-422
88. Yi M., Villanova R.A., Thomas D.L., et al. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci USA 103 (2006) 2310-2315
89. Weiner A.J., Paliard X., Selby M.J., et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol 75 (2001) 7142-7148
90. Mehta S.H., Cox A., Hoover D.R., et al. Protection against persistence of hepatitis C. Lancet 359 (2002) 1478-1483
91. Reali E., Houghton M., and Abrignani S. Hepatitis C virus vaccines. In: Plotkin S., Orenstein W., and Offit P. (Eds). Vaccines. 5th ed. (2008), Saunders Elsevier 1187-1199
92. Sypsa V., Touloumi G., Tassopoulos N.C., et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat 11 (2004) 366-374
93. Roy K., Hay G., Andragetti R., et al. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 129 (2002) 577-585
94. Centers for Disease Control and Prevention. Recommendations for Postexposure Interventions to Prevent Infection with Hepatitis B Virus, Hepatitis C Virus, or Human Immunodeficiency Virus, and Tetanus in People Wounded During Bombings and Other Mass-Casualty Events -- United States (2008). Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5706a1.htm?s_cid=rr5706a1_e [accessed 01.08.08]
95. Kamal S.M., Moustafa K.N., Chen J., et al. Duration of peginterferon therapy in acute hepatitis C: A randomized trial. Hepatology 43 (2006) 923-931